Tag Archives: MDGL

Madrigal Pharmaceuticals Inc (MDGL) Receives a Rating Update from a Top Analyst

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Madrigal Pharmaceuticals Inc (MDGL – Research Report) today. The company’s shares opened today at $210.34. According to TipRanks.com, Baral is a top 100 analyst with an average return of

Oppenheimer Remains a Buy on Madrigal Pharmaceuticals Inc (MDGL)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Madrigal Pharmaceuticals Inc (MDGL – Research Report), with a price target of $300. The company’s shares closed yesterday at $208.38. Olson commented: “MDGL released 3Q18 financial

Madrigal Pharmaceuticals Inc (MDGL) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) today and set a price target of $300. The company’s shares opened today at $203.20. Olson said: “Viking Therapeutics announced positive top line data from a

Analysts Have Conflicting Sentiments on These Healthcare Companies: Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) and NovaBay Pharma (NYSE: NBY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and NovaBay Pharma (NYSE:NBY). Madrigal Pharmaceuticals Inc (MDGL) In a report released yesterday, Yasmeen Rahimi from Roth Capital reiterated

Madrigal Pharmaceuticals Inc (MDGL) Receives a Buy from Oppenheimer

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), with a price target of $300. The company’s shares closed yesterday at $245.51. Olson said: “MDGL provided 2Q18 financial results that

What Did This CEO Just Do with Personal Shares of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)?

Yesterday, the CEO of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), Paul A. Friedman, sold shares of MDGL for $21.14M. In addition to Paul A. Friedman, 4 other MDGL executives reported Sell trades in the last month. This is Friedman’s first transaction